Welcome to our dedicated news page for Revelation Biosciences (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences .
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Revelation Biosciences 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Revelation Biosciences 's position in the market.
Rhea-AI Summary
Revelation Biosciences, Inc. (REVB) reports financial results for the three and twelve months ended December 31, 2023. The company completed a $6.2 million public offering and initiated a Phase 1 clinical study of Gemini. Positive nonclinical data on Gemini's impact on acute kidney injury was presented at a conference. Revelation had $12.0 million in cash and cash equivalents as of December 31, 2023, compared to $5.3 million in 2022. The net loss for the three months ended December 31, 2023, was $2.2 million, with a basic and diluted net loss per share of $8.33, while the net loss for the twelve months ended December 31, 2023, was $0.1 million, with a basic and diluted net loss per share of $0.53.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
-
Rhea-AI Summary
Revelation Biosciences Inc. (NASDAQ: REVB) announces positive preclinical data on Gemini's potential therapeutic benefits for acute kidney injury. Results show significant improvements in kidney function, reduced tissue damage, and inflammation markers. The company is optimistic about Gemini's ability to treat inflammatory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
-
Rhea-AI Summary
Revelation Biosciences Inc. (REVB) CEO, James Rolke, to participate in a virtual fireside chat at the 36th Annual Roth Conference. The event will take place on March 17-19, 2023, at The Ritz Carlton, Laguna Niguel, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
Rhea-AI Summary
Revelation Biosciences Inc. (NASDAQ: REVB) initiates Phase 1 clinical study for Gemini, a TLR4 agonist, to prevent acute kidney injury and post-surgical infections. Top-line data on safety, tolerability, and biomarker activity expected this summer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.32%
Tags
-
Rhea-AI Summary
Revelation Biosciences Inc. (REVB) will present new preclinical data on Gemini, a potential therapy for acute kidney injury, at The 29th International Conference on Advances in Critical Care Nephrology. The company aims to address the unmet medical need for AKI prevention and hospital-acquired infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
-
Rhea-AI Summary
Revelation Biosciences Inc. announced the closing of a public offering, raising approximately $6.2 million. The company plans to use the net proceeds for the development of various clinical studies and products, as well as for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.75%
Tags
Rhea-AI Summary
Revelation Biosciences Inc. (NASDAQ: REVB) announced the pricing of a public offering of 1,365,000 shares of its common stock, along with warrants to purchase up to 2,730,000 shares at an offering price of $4.53 per share. The closing of the offering is expected to occur on or around April 6, 2021. The company plans to use the net proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-63.86%
Tags
-
Rhea-AI Summary
Revelation Biosciences Inc. (NASDAQ: REVB) announced the presentation of new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) at an upcoming conference. The data will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) in San Diego. Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist, in development for prevention of AKI and hospital acquired infection. The presentation will be made by Robin Marsden, Senior Vice President of Biology, Revelation Biosciences. The CEO, James Rolke, expressed excitement about the opportunity to share their preclinical data for the prevention of AKI at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.8%
Tags
-
Rhea-AI Summary
Revelation Biosciences Inc. (REVB) has announced a 1-for-30 reverse stock split of its common stock, effective January 25, 2024, to increase the market price per share and regain compliance with Nasdaq listing requirements. The reverse stock split will affect all stockholders uniformly, with adjustments to warrants, restricted stock unit awards, and stock options. The CUSIP number for the common stock will change to 76135L507 post-split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.38%
Tags
Rhea-AI Summary
Revelation Biosciences, Inc. (NASDAQ: REVB) reported its financial results for the three and nine months ended September 30, 2023. The company highlighted recent biomarker data showing the pharmacologic activity of Gemini in preclinical studies, presented at a healthcare conference, and announced the upcoming start of a Phase 1 clinical study. Financially, Revelation had $14.0 million in cash and cash equivalents as of September 30, 2023, with sufficient funds to support operations through September 2024. The net loss for the three months ended September 30, 2023, was $2.6 million, while the net income for the nine months ended September 30, 2023, was $2.1 million, primarily due to the change in fair value of the warrant liability creating an $8.3 million gain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.89%
Tags
Revelation Biosciences, Inc.
Nasdaq:REVB
REVB Rankings
REVB Stock Data
3.51M
1.63M
0.32%
1.96%
2.01%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
SAN DIEGO
About REVB
we develop immunologic therapeutics and diagnostics designed to make the world a healthier place